XML 80 R44.htm IDEA: XBRL DOCUMENT v3.20.4
The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019: (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Accumulated Amortization $ (748,627) $ (478,983)
Intangible Assets, Gross (Excluding Goodwill) 5,996,350 5,737,194
Intangible assets, net 5,247,723 5,258,211
Multiple Trademarks [Member]    
Finite-Lived Intangible Assets [Line Items]    
Indefinite-Lived Trademarks 323,341 294,813
Indefinite-lived Intangible Assets (Excluding Goodwill) 323,341 294,813
Approved Hormone Therapy Drug Candidate Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Gross 4,044,552 3,463,082
Finite-Lived Intangible Assets, Accumulated Amortization (748,627) (478,983)
Finite-Lived Intangible Assets, Net $ 3,295,925 $ 2,984,099
Finite-Lived Intangible Assets, Remaining Amortization Period 12 years 13 years
Hormone Therapy Drug Candidate Patents - (Pending) [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Gross $ 1,628,457 $ 1,979,299
Finite-Lived Intangible Assets, Net $ 1,628,457 $ 1,979,299